Carsgen's claudin18.2 car-t therapy satri-cel granted breakthrough therapy designation by the nmpa

Shanghai , march 2, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the center for drug evaluation (cde) of china's national medical products administration (nmpa) has granted breakthrough therapy designation (btd) to satricabtagene autoleucel ("satri-cel", ct041) for the treatment of claudin18.2-positive advanced gastric/gastroesophageal junction cancer (g/gej) in patients who have failed at least two prior lines of therapy. the company plans to submit a new drug application (nda) for satri-cel to the nmpa in the first half of 2025.
CAR Ratings Summary
CAR Quant Ranking